Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Olanzapine; Risperidone

Criteria

Inclusion Criteria:

• 18-65 years old

• Diagnosed with Schizophrenia or Schizoaffective disorder

• Ability to visit the doctor's office for scheduled visits

Exclusion Criteria:

• Women who are pregnant or breastfeeding

• Have a body mass index (BMI) greater than 40

• Have diabetes, heart disease or any other unstable illness

• Have known positive human immunodeficiency virus (HIV)

• Are currently taking olanzapine, risperidone, clozapine, glucocorticoids, injectable antipsychotics